Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alison Young

Dermatology Seattle, WA Medical Doctor

NPI 1891734893 CMS profile 313085

805 Madison St Ste 703, Seattle, WA 98104

Open in the dashboard

General payments

$53,232

1,626 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alison Young of Seattle, WA is reported in the CMS Open Payments database as having received $53,232 across 1,626 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,877 343
2024 General $19,031 311
2023 General $8,789 264
2022 General $8,323 223
2021 General $5,931 223
2020 General $1,755 123
2019 General $3,526 139

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alison Young
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Alison Young were reported at $5,877. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Alison Young Dermatology median Middle half National median
2019 $3,526 $454 $129–$1,240 $163
2020 $1,755 $235 $81–$756 $114
2021 $5,931 $377 $108–$1,108 $132
2022 $8,323 $514 $143–$1,391 $149
2023 $8,789 $607 $159–$1,674 $160
2024 $19,031 $751 $204–$1,903 $164
2025 $5,877 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. LEO Pharma Inc. $7,266 91 payments
  2. Incyte Corporation $5,849 79 payments
  3. AbbVie, Inc. $5,811 240 payments
  4. Janssen Biotech, Inc. $4,413 326 payments
  5. E.R. Squibb & Sons, L.L.C. $4,006 37 payments
  6. Sun Pharmaceutical Industries Inc. $3,531 51 payments
  7. Dermavant Sciences, Inc. $3,390 21 payments
  8. Biofrontera Inc. $2,912 19 payments
  9. Lilly USA, LLC $2,245 93 payments
  10. Genzyme Corporation $1,863 90 payments
  11. Other $11,948 579 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $29,260 1,605 payments
  2. Consulting Fee $22,416 11 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,000 1 payment
  4. Education $556 9 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $5,120 273 payments
  2. VTAMA $3,452 25 payments
  3. DUPIXENT $2,075 104 payments
  4. SKYRIZI $1,897 122 payments
  5. TALTZ $1,803 78 payments
  6. BF-RhodoLED $1,713 15 payments
  7. Ameluz $1,609 8 payments
  8. RINVOQ $1,413 74 payments
  9. OPZELURA $1,402 75 payments
  10. CIBINQO $1,309 84 payments
  11. Other $21,582 1,077 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

880

Median for Dermatology: 534

Drug cost

$123,944

Median for Dermatology: $67,151

Branded share of claims

5.3%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rinvoq Upadacitinib Brand 16 $101,249
Clobetasol Propionate Generic 97 $4,161
Fluorouracil Generic 46 $3,560
Tacrolimus Generic 19 $1,613
Minoxidil Generic 124 $1,459
Econazole Nitrate Generic 33 $1,449
Tretinoin Generic 37 $1,407
Betamethasone Dipropionate Generic 34 $1,376
Ketoconazole Generic 104 $1,364
Hydroxychloroquine Sulfate Generic 31 $1,279

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$166,348

Of which drugs: $17,275

Medicare patients

455

Average age 75

Services billed

12,986

300 women, 155 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 47%
Arthritis 45%
Osteoporosis 21%
Cancer 18%
Depression 14%
Ischemic heart disease 13%
Atrial fibrillation 11%
Diabetes 10%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 49 10,600 $14,170

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

1,626 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record